developed mannose‐modified macrophage‐derived microparticles (Man‐MPs, in which MPs were also denoted as microvesicles (MiVs)) for targeting M2‐like TAMs by delivery of TAMs‐repolarization drug metformin (Met@Man‐MPs), which efficiently reversed tumor‐supportive TAMs into anti‐tumor M1 phenotype.[250] Because macrophages express MMPs, Met@ManMPs promoted tumor ECM degradation and significantly facilitated tumor penetration and tumor accumulation of anti‐PD‐1 antibody, which elicited CD8+ T cell immunity and boosted anti‐PD‐1 immunotherapy. The gene discussed is CD8A; the disease is neoplasm.